Design and Synthesis of Pyrazole-Based Macrocyclic Kinase Inhibitors Targeting BMPR2-Reference-Cited by-同舟云学术

Design and Synthesis of Pyrazole-Based Macrocyclic Kinase Inhibitors Targeting BMPR2

Published:2023-05-30 Issue:6 Volume:14 Page:833-840
ISSN:1948-5875
Container-title:ACS Medicinal Chemistry Letters
language:en
Short-container-title:ACS Med. Chem. Lett.

Author:

Amrhein Jennifer A.¹²,Wang Guiqun¹²³^ORCID,Berger Benedict-Tilman¹²^ORCID,Berger Lena M.¹²^ORCID,Kalampaliki Amalia D.⁴,Krämer Andreas¹²³,Knapp Stefan¹²³^ORCID,Hanke Thomas¹²^ORCID

Affiliation:

1. Institute for Pharmaceutical Chemistry, Johann Wolfgang Goethe-University, Max-von-Laue-Str. 9, D-60438 Frankfurt am Main, Germany

2. Structure Genomics Consortium, Buchmann Institute for Molecular Life Sciences, Johann Wolfgang Goethe-University, Max-von-Laue-Str. 15, D-60438 Frankfurt am Main, Germany

3. German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), DKTK Site Frankfurt-Mainz, 69120 Heidelberg, Germany

4. Department of Pharmacy, Division of Pharmaceutical Chemistry, National and Kapodistrian University of Athens, Panepistimiopolis, Zografou, 15771 Athens, Greece

Funder

Bayer

Merck KGaA

Genentech

Takeda Pharmaceutical Company

Pfizer

Innovative Medicines Initiative

Bristol-Myers Squibb

Genome Canada

H2020 Health

Boehringer Ingelheim

Janssen